Cargando…

A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study

BACKGROUND: Chemoprevention crossover trials of tea can be more efficient than parallel designs but the attrition and compliance rates with such trials are unknown. METHODS: Attrition (dropouts) and compliance with treatment were assessed in a 25-week randomized, placebo controlled, crossover, feasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dash, Chiranjeev, Chung, Fung-Lung, Rohan, Joy Ann Phillips, Greenspan, Emily, Christopher, Patrick D, Makambi, Kepher, Hara, Yukihiko, Newkirk, Kenneth, Davidson, Bruce, Adams-Campbell, Lucile L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414766/
https://www.ncbi.nlm.nih.gov/pubmed/22800470
http://dx.doi.org/10.1186/1472-6882-12-96
_version_ 1782240251792588800
author Dash, Chiranjeev
Chung, Fung-Lung
Rohan, Joy Ann Phillips
Greenspan, Emily
Christopher, Patrick D
Makambi, Kepher
Hara, Yukihiko
Newkirk, Kenneth
Davidson, Bruce
Adams-Campbell, Lucile L
author_facet Dash, Chiranjeev
Chung, Fung-Lung
Rohan, Joy Ann Phillips
Greenspan, Emily
Christopher, Patrick D
Makambi, Kepher
Hara, Yukihiko
Newkirk, Kenneth
Davidson, Bruce
Adams-Campbell, Lucile L
author_sort Dash, Chiranjeev
collection PubMed
description BACKGROUND: Chemoprevention crossover trials of tea can be more efficient than parallel designs but the attrition and compliance rates with such trials are unknown. METHODS: Attrition (dropouts) and compliance with treatment were assessed in a 25-week randomized, placebo controlled, crossover, feasibility clinical trial of four tea treatments to investigate the effect of tea on oral cancer biomarkers. Each treatment lasted 4 weeks with 2 weeks of washout in between. Participants were 32 smokers and 33 non-smokers without any evidence of premalignant oral lesions. The interventions consisted of packets of green tea, black tea, caffeinated water, or placebo. Participants were assigned to each treatment for four weeks, and were instructed to drink five packets per day while on the treatment. Dropout from the trial and compliance (consumption of ≥ 85% of the prescribed treatment packets) are the main outcome measures reported. RESULTS: There was a high rate of dropout (51%) from the study, and the rates were significantly higher among smokers (64%) than non-smokers (36%). Among participants who completed the study the rate of compliance was 72%. The highest rates of dropouts occurred between the first and second treatment visits in both smokers (38% dropout) and non-smokers (18% dropout). Throughout the study smokers were more likely to dropout than non-smokers. Black tea treatment was associated with the highest rates of dropout among smokers (37%), but was associated with the lowest rate of dropout among non-smokers (4%). CONCLUSIONS: In a study conducted to test the feasibility of a four-treatment crossover tea trial, a high rate of dropout among smokers and non-smokers was observed. Multi-arm crossover tea trials might pose a higher burden on participants and research is needed to improve adherence and treatment compliance in such trials. TRIAL REGISTRATION NUMBER: ISRCTN70410203
format Online
Article
Text
id pubmed-3414766
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34147662012-08-10 A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study Dash, Chiranjeev Chung, Fung-Lung Rohan, Joy Ann Phillips Greenspan, Emily Christopher, Patrick D Makambi, Kepher Hara, Yukihiko Newkirk, Kenneth Davidson, Bruce Adams-Campbell, Lucile L BMC Complement Altern Med Research Article BACKGROUND: Chemoprevention crossover trials of tea can be more efficient than parallel designs but the attrition and compliance rates with such trials are unknown. METHODS: Attrition (dropouts) and compliance with treatment were assessed in a 25-week randomized, placebo controlled, crossover, feasibility clinical trial of four tea treatments to investigate the effect of tea on oral cancer biomarkers. Each treatment lasted 4 weeks with 2 weeks of washout in between. Participants were 32 smokers and 33 non-smokers without any evidence of premalignant oral lesions. The interventions consisted of packets of green tea, black tea, caffeinated water, or placebo. Participants were assigned to each treatment for four weeks, and were instructed to drink five packets per day while on the treatment. Dropout from the trial and compliance (consumption of ≥ 85% of the prescribed treatment packets) are the main outcome measures reported. RESULTS: There was a high rate of dropout (51%) from the study, and the rates were significantly higher among smokers (64%) than non-smokers (36%). Among participants who completed the study the rate of compliance was 72%. The highest rates of dropouts occurred between the first and second treatment visits in both smokers (38% dropout) and non-smokers (18% dropout). Throughout the study smokers were more likely to dropout than non-smokers. Black tea treatment was associated with the highest rates of dropout among smokers (37%), but was associated with the lowest rate of dropout among non-smokers (4%). CONCLUSIONS: In a study conducted to test the feasibility of a four-treatment crossover tea trial, a high rate of dropout among smokers and non-smokers was observed. Multi-arm crossover tea trials might pose a higher burden on participants and research is needed to improve adherence and treatment compliance in such trials. TRIAL REGISTRATION NUMBER: ISRCTN70410203 BioMed Central 2012-07-16 /pmc/articles/PMC3414766/ /pubmed/22800470 http://dx.doi.org/10.1186/1472-6882-12-96 Text en Copyright ©2012 Dash et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Dash, Chiranjeev
Chung, Fung-Lung
Rohan, Joy Ann Phillips
Greenspan, Emily
Christopher, Patrick D
Makambi, Kepher
Hara, Yukihiko
Newkirk, Kenneth
Davidson, Bruce
Adams-Campbell, Lucile L
A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
title A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
title_full A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
title_fullStr A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
title_full_unstemmed A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
title_short A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
title_sort six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414766/
https://www.ncbi.nlm.nih.gov/pubmed/22800470
http://dx.doi.org/10.1186/1472-6882-12-96
work_keys_str_mv AT dashchiranjeev asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT chungfunglung asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT rohanjoyannphillips asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT greenspanemily asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT christopherpatrickd asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT makambikepher asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT harayukihiko asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT newkirkkenneth asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT davidsonbruce asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT adamscampbelllucilel asixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT dashchiranjeev sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT chungfunglung sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT rohanjoyannphillips sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT greenspanemily sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT christopherpatrickd sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT makambikepher sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT harayukihiko sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT newkirkkenneth sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT davidsonbruce sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy
AT adamscampbelllucilel sixmonthcrossoverchemopreventionclinicaltrialofteainsmokersandnonsmokersmethodologicalissuesinafeasibilitystudy